4.3 Article

Patient dosimetry for 90Y selective internal radiation treatment based on 90Y PET imaging

Journal

JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
Volume 14, Issue 5, Pages 212-221

Publisher

MULTIMED INC
DOI: 10.1120/jacmp.v14i5.4371

Keywords

yttrium-90 microsphere; liver cancer; PET; dosimetry; LQ model

Ask authors/readers for more resources

Until recently, the radiation dose to patients undergoing the Y-90 selective internal radiation treatment (SIRT) procedure is determined by applying the partition model to Tc-99m MAA pretreatment scan. There can be great uncertainty in radiation dose calculated from this approach and we presented a method to compute the 3D dose distributions resulting from Y-90 SIRT based on Y-90 positron emission tomography (PET) imaging. Five Y-90 SIRT treatments were retrospectively analyzed. After Y-90 SIRT, patients had Y-90 PET/CT imaging within 6 hours of the procedure. To obtain the 3D dose distribution of the patients, their respective Y-90 PET images were convolved with a Monte Carlo generated voxel dose kernel. The sensitivity of the PET/CT scanner for Y-90 was determined through phantom studies. The 3D dose distributions were then presented in DICOM RT dose format. By applying the linear quadratic model to the dose data, we derived the biologically effective dose and dose equivalent to 2 Gy/fraction delivery, taking into account the spatial and temporal dose rate variations specific for SIRT. Based on this data, we intend to infer tumor control probability and risk of radiation induced liver injury from SIRT by comparison with established dose limits. For the five cases, the mean dose to target ranged from 51.7 +/- 28.6 Gy to 163 +/- 53.7 Gy. Due to the inhomogeneous nature of the dose distribution, the GTVs were not covered adequately, leading to very low values of tumor control probability. The mean dose to the normal liver ranged from 21.4 +/- 30.7 to 36.7 +/- 25.9 Gy. According to QUANTEC recommendation, a patient with primary liver cancer and a patient with metastatic liver cancer has more than 5% risk of radiotherapy-induced liver disease (RILD).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available